Table 2.

Comparison of patients studied with those receiving the Children's Cancer Group (CCG) 2891 protocol and correlation of LOH with age, sex, white blood cell (WBC) count, and prognosis

Patient characteristicLOH study, % (n = 47)CCG 2891, % (n = 844)PLOH, %
(n = 14)		No LOH, % (n = 33)P
Age at diagnosis, y       
 0-1.99  0 21   0  0  
 2-9.99 38 39  29 42  
 Older than 10 62 40 .0005* 71 58 .37* 
Sex       
 Male 62 51  50 67  
 Female 38 49 .19* 50 33 .46* 
WBC       
 Below 20 × 109/L 34 49   7 46  
 20-100 × 109/L 43 34  64 33  
 Above 100 × 109/L 23 17 .13* 29 21 .035* 
 Median 40 20 .010† 62 29 .061† 
Induction outcome       
 Remission 58 78  80 50  
 Failure 35 15  20 40 .22* 
 Death  7  7 .0025*  0 10  
Overall survival, %‡       
 Not stratified by WBC 40 ± 8 [46] 34 ± 2 [844] .89 51 ± 15 [14] 34 ± 8 [32] .11 
 WBC below 20 × 109/L 38 ± 12 [16] 43 ± 2 [415] .22 100 [1] 33 ± 12 [15] .31  
 WBC 20-100 × 109/L 54 ± 13 [19] 30 ± 3 [285] .053 58 ± 20 [9] 50 ± 16 [10] .28 
 WBC above 100 × 109/L 18 ± 12 [11] 24 ± 4 [144] .20 25 ± 22 [4] 14 ± 13 [7] .99 
 WBC above 20 × 109/L 41 ± 10 [30] 27 ± 2 [429] .32 49 ± 15 [13] 35 ± 12 [17] .22 
Patient characteristicLOH study, % (n = 47)CCG 2891, % (n = 844)PLOH, %
(n = 14)		No LOH, % (n = 33)P
Age at diagnosis, y       
 0-1.99  0 21   0  0  
 2-9.99 38 39  29 42  
 Older than 10 62 40 .0005* 71 58 .37* 
Sex       
 Male 62 51  50 67  
 Female 38 49 .19* 50 33 .46* 
WBC       
 Below 20 × 109/L 34 49   7 46  
 20-100 × 109/L 43 34  64 33  
 Above 100 × 109/L 23 17 .13* 29 21 .035* 
 Median 40 20 .010† 62 29 .061† 
Induction outcome       
 Remission 58 78  80 50  
 Failure 35 15  20 40 .22* 
 Death  7  7 .0025*  0 10  
Overall survival, %‡       
 Not stratified by WBC 40 ± 8 [46] 34 ± 2 [844] .89 51 ± 15 [14] 34 ± 8 [32] .11 
 WBC below 20 × 109/L 38 ± 12 [16] 43 ± 2 [415] .22 100 [1] 33 ± 12 [15] .31  
 WBC 20-100 × 109/L 54 ± 13 [19] 30 ± 3 [285] .053 58 ± 20 [9] 50 ± 16 [10] .28 
 WBC above 100 × 109/L 18 ± 12 [11] 24 ± 4 [144] .20 25 ± 22 [4] 14 ± 13 [7] .99 
 WBC above 20 × 109/L 41 ± 10 [30] 27 ± 2 [429] .32 49 ± 15 [13] 35 ± 12 [17] .22 
*

By χ2 test.

†

By Mann-Whitney U test.

‡

Values in square brackets are numbers of patients, and allP values in the survival analysis were obtained by using log-rank tests. For patients in the LOH study and those receiving the CCG 2891 protocol, plus-minus values are for overall survival at 9 years; for patients in the LOH and no-LOH groups, plus-minus values are for overall survival from entry into the study (8 years).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal